New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis
About 70% of bladder cancers (BCs) are diagnosed as non-muscle-invasive BCs (NMIBCs), while the remaining are muscle-invasive BCs (MIBCs). The European Association of Urology (EAU) guidelines stratify NMIBCs into low, intermediate, and high risk for treatment options. Low-risk NMIBCs undergo only th...
Main Authors: | Katia Pane, Peppino Mirabelli, Luigi Coppola, Ester Illiano, Marco Salvatore, Monica Franzese |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Chemistry |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fchem.2020.00600/full |
Similar Items
-
Intravesical immunotherapy in nonmuscle invasive bladder cancer
by: Jan-Friedrich Jokisch, et al.
Published: (2015-01-01) -
Single course of intravesical Bacillus Calmette–Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: A prospective randomized study
by: Mohamed Bakr Mohamed, et al.
Published: (2020-01-01) -
Granulomatous Hepatitis Following Intra-Vesical Instillation of Bacillus Calmette–Guérin for Treatment of Bladder Cancer
by: Elsa Alves Branco, et al.
Published: (2021-07-01) -
Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature
by: Oreoluwa Oladiran, et al.
Published: (2020-03-01) -
Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette–Guerin: A single center experience and analysis of prognostic factors
by: Shouki N Bazarbashi, et al.
Published: (2016-01-01)